Ali Khademhosseini, Ph.D., is the CEO of the Terasaki Institute for Biomedical Innovation. He was the Founding Director of the Center for Minimally Invasive Therapeutics at UCLA. He joined UCLA starting from Nov. 2017 from Harvard University, where he was a Professor at Harvard Medical School (HMS) and faculty at the Harvard-MIT’s Division of Health Sciences and Technology (HST), Brigham and Women’s Hospital (BWH) as well as an associate faculty at the Wyss Institute for Biologically Inspired Engineering. He is a leader in applying bioengineering solutions to precision medicine. His large interdisciplinary research team is interested in developing ‘personalized’ solutions that utilize micro- and nanoscale technologies to enable a range of therapies for organ failure, cardiovascular disease, and cancer. In enabling this vision, he works closely with clinicians (including interventional radiologists, cardiologists, and surgeons). He has developed numerous techniques in controlling the behavior of patient-derived cells to engineer artificial tissues and cell-based therapies. He is also developing ‘organ-on-a-chip’ systems that aim to mimic human physiology and pathology to enable patient-specific evaluation of drug candidates.